Syndax Pharmaceuticals Inc

Ownership Transactions Reported by 18 Insiders

Symbol
SNDX on Nasdaq
Industry
Pharmaceutical Preparations
Location
730 Third Avenue, 9 Th Floor, New York, NY

Insiders trading volume in the past year

Syndax Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Michael A. Metzger Chief Executive Officer, Director $4.9M -$2.98M -37.8% Sep 8, 2025
Steve M. Sabus Chief Commercial Officer $4.26M Dec 5, 2022
Dennis Podlesak Director $3.04M -$875K -22.4% Aug 14, 2025
Neil Gallagher President, Head of R&D $2.94M -$71.6K -2.38% Feb 10, 2025
Keith A. Goldan Chief Financial Officer $2.41M -$70.6K -2.85% Jul 31, 2025
Catherine Madigan Chief Medical Officer $2.13M Feb 2, 2023
Jennifer Jarrett Director $1.8M Feb 5, 2025
Pierre Legault Director $1.8M Feb 5, 2025
William Meury Director $1.8M Feb 5, 2025
Aleksandra Rizo Director $1.28M Feb 5, 2025
Keith Katkin Director $911K +$91.1K +11.1% May 19, 2025
Michael L. Meyers SVP, Chief Medical Officer $761K Feb 2, 2022
Martin H. Huber Jr. Director $710K +$45K +6.76% May 19, 2025
Briggs Morrison Director $636K Feb 7, 2024
Fabrice Egros Director $584K Feb 2, 2022
Alexander Nolte Chief Accounting Officer $329K Feb 2, 2023
Nicholas A.J. Botwood Head of R&D, CMO $316K +$106K +50.3% May 16, 2025
Peter Ordentlich Chief Scientific Officer Feb 15, 2023

Recent Insider Transactions by Companies or Individuals for Syndax Pharmaceuticals Inc

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.